Arthur Bobin
French Institute of Health and Medical Research
30 Papers
35 Citations
Arthur Bobin is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Medicine & Multiple myeloma. The author has an hindex of 5, co-authored 15 publications.
Chat about Author
Papers
Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020.
Arthur Bobin,Evelyne Liuu,Niels Moya,Cécile Gruchet,Florence Sabirou,Anthony Levy,Helene Gardeney,Laly Nsiala,Laura Cailly,Stéphanie Guidez,Cécile Tomowiak,Thomas Systchenko,Vincent Javaugue,Geraldine Durand,Xavier Leleu,Mathieu Puyade +15 more
TL;DR: The most recent advances in MM therapeutics, which have undergone major transformations over the past decade, are enumerated and comment on.
27
Response to pneumococcal vaccination in multiple myeloma
Loïc Renaud,Susanna Schraen,Guillemette Fouquet,Stéphanie Guidez,Hélène Demarquette,Morgane Nudel,Emilie Cayssials,Claire Bories,Charles Herbaux,Thomas Systchenko,Jean-Luc Faucompré,Antoine Machet,Florence Sabirou,Antony Levy,Arthur Bobin,Valentine Richez,Niels Moya,Cécile Gruchet,Deborah Desmier,Zoé Van de Wyngaert,Benjamin Carpentier,Salomon Manier,Thierry Facon,Stephen Harding,Xavier Leleu +24 more
TL;DR: In this article, a longitudinal response data to pneumococcal vaccination in multiple myeloma patients was presented, and the primary endpoint was the incidence rate of patients who obtained an isotype response serum concentration after vaccination.
21
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.
Guillemette Fouquet,Stéphanie Guidez,Valentine Richez,Anne-Marie Stoppa,Christophe Le Tourneau,Margaret Macro,Cécile Gruchet,Arthur Bobin,Niels Moya,Thomas Syshenko,Florence Sabirou,Anthony Levy,Paul Franques,Helene Gardeney,Lionel Karlin,Lotfi Benboubker,M. Ouali,Jean-Claude Vedovato,Pierre Ferré,Mariya Pavlyuk,Michel Attal,Thierry Facon,Xavier Leleu +22 more
TL;DR: This study suggests that egression of tumor cells to the blood stream can represent a novel therapeutic strategy for MM, however, because of significant hematological toxicity, this study had to be discontinued.
Recent advances in the treatment of multiple myeloma: a brief review
Arthur Bobin,Xavier Leleu +1 more
TL;DR: The recent history of multiple myeloma has been marked by tremendous advances in the treatments available, which have ultimately improved the patients' survival as mentioned in this paper , which has led to the development of modern immunological treatments such as CAR-T cells or bispecific antibodies.
Carfilzomib weekly 20/56 mg/m2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.
Valentine Richez,Cécile Gruchet,Stéphanie Guidez,Guillemette Fouquet,Isabelle Azais,Geraldine Durand,Vincent Javaugue,Antoine Brigaud,Florent Plasse,Jeremie Diolez,Antoine Machet,Niels Moya,Helene Gardeney,Paul Franques,Arthur Bobin,Anthony Levy,Florence Sabirou,Anthony Bonnin,Celine Dieval,Sylvain Primault,Jocelyn Barrier,Emmanuel Fleck,Sabrina Bouyier,Claire Daras,Isabelle Princet,Delphine Bauwens,Laurence Legros,Jean-Gabriel Fuzibet,Angela Gil,Frank Bridoux,Hervé Avet-Loiseau,Xavier Leleu +31 more
TL;DR: Results indicated that improved patient-reported outcomes, especially increased adherence, are significant mediators of the association between treatment with deferasirox DT vs FCT, and the reduction from baseline in serum ferritin achieved over 6 months of treatment.
8